Physician profile
Swati Vijaylakshmi Elchuri
NPI 1750569133
$210,325.43
in general payments reported to CMS, 2019-2025
22 companies · $79K in 2025
The $79K reported for 2025 was more than what 99% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $155 · 2020: $99.02 · 2021: $143 · 2022: $386 · 2023: $35K · 2024: $96K · 2025: $79K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $171K · Travel and Lodging: $31K · Food and Beverage: $6,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,392.23 |
| Travel and Lodging | $31,266.19 |
| Food and Beverage | $6,884.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $194,246.19 | 2023-2025 | |
| Genzyme Corporation | $7,037.78 | 2025 | |
| Insulet Corporation | $6,548.32 | 2019-2025 | Omnipod, Omnipod |
| Medtronic, INC. | $461.52 | 2021-2024 | Minimed 780g |
| Dexcom, INC. | $419.38 | 2019-2025 | Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $348.46 | 2022-2025 | Skytrofa |
| Novo Nordisk INC | $270.33 | 2024-2025 | Sogroya, Wegovy |
| Tolmar, INC. | $168.52 | 2024-2025 | Fensolvi |
| Amphastar Pharmaceuticals, INC. | $149.41 | 2024-2025 | |
| Abbvie INC. | $110.96 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $108.68 | 2023-2025 | Triptodur, Triptodur |
| Medtronic Minimed, INC. | $101.20 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $94.42 | 2024-2025 | |
| Kyowa Kirin, INC. | $49.00 | 2023-2025 | Crysvita |
| Abbott Laboratories | $39.09 | 2022-2024 | Freestyle Libre 3 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $38.44 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $38.17 | 2024-2025 | |
| Sequel Med Tech, LLC | $23.50 | 2025 | Twiist |
| Companion Medical, INC. | $20.19 | 2020 | |
| Sarepta Therapeutics, INC. | $18.02 | 2019 | |
| Tandem Diabetes Care, INC. | $17.71 | 2022 | |
| Beta Bionics, INC. | $16.14 | 2024 | Ilet Bionic Pancreas |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swati Elchuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.